CA3068153A1 - Plasminogen treatment of conditions associated with pai-1 overexpression - Google Patents
Plasminogen treatment of conditions associated with pai-1 overexpression Download PDFInfo
- Publication number
- CA3068153A1 CA3068153A1 CA3068153A CA3068153A CA3068153A1 CA 3068153 A1 CA3068153 A1 CA 3068153A1 CA 3068153 A CA3068153 A CA 3068153A CA 3068153 A CA3068153 A CA 3068153A CA 3068153 A1 CA3068153 A1 CA 3068153A1
- Authority
- CA
- Canada
- Prior art keywords
- plasminogen
- pai
- disease
- subject
- overexpression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523901P | 2017-06-23 | 2017-06-23 | |
| US62/523,901 | 2017-06-23 | ||
| PCT/IB2018/000655 WO2018234861A1 (en) | 2017-06-23 | 2018-06-22 | PLASMINOGEN TREATMENT OF AFFECTIONS ASSOCIATED WITH OVEREXPRESSION OF PAI-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3068153A1 true CA3068153A1 (en) | 2018-12-27 |
Family
ID=64737041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3068153A Pending CA3068153A1 (en) | 2017-06-23 | 2018-06-22 | Plasminogen treatment of conditions associated with pai-1 overexpression |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11826404B2 (enExample) |
| EP (1) | EP3641888B1 (enExample) |
| JP (1) | JP2020524689A (enExample) |
| KR (1) | KR20200019217A (enExample) |
| CN (1) | CN110831668B (enExample) |
| AU (1) | AU2018287316B2 (enExample) |
| BR (1) | BR112019027229A2 (enExample) |
| CA (1) | CA3068153A1 (enExample) |
| CL (1) | CL2019003789A1 (enExample) |
| DK (1) | DK3641888T3 (enExample) |
| ES (1) | ES2965937T3 (enExample) |
| FI (1) | FI3641888T3 (enExample) |
| IL (1) | IL271470B2 (enExample) |
| MX (1) | MX2019015741A (enExample) |
| MY (1) | MY203136A (enExample) |
| RU (1) | RU2020100080A (enExample) |
| SG (1) | SG11201912813SA (enExample) |
| TW (1) | TWI868051B (enExample) |
| WO (1) | WO2018234861A1 (enExample) |
| ZA (1) | ZA202000280B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI677348B (zh) | 2016-12-15 | 2019-11-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種改善心臟病變的方法 |
| TWI750189B (zh) | 2016-12-15 | 2021-12-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療冠狀動脈粥樣硬化及其併發症的方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| TWI787732B (zh) * | 2020-02-06 | 2022-12-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種預防和治療多發性硬化症的方法和藥物 |
| CN115666625A (zh) * | 2020-03-24 | 2023-01-31 | 泰伦基国际有限公司 | 一种促进错误折叠蛋白及其聚集物降解的方法和药物 |
| US20230173039A1 (en) * | 2020-03-24 | 2023-06-08 | Talengen International Limited | Method and drug for treating alzheimer disease |
| KR20220158036A (ko) * | 2020-03-24 | 2022-11-29 | 탈렌젠 인터내셔널 리미티드 | 파킨슨병의 치료 방법 및 약물 |
| CN112174979B (zh) * | 2020-10-27 | 2021-09-07 | 黑龙江中医药大学 | 一种治疗多囊卵巢综合征的药物及其制备方法 |
| WO2026006092A1 (en) * | 2024-06-24 | 2026-01-02 | The Cleveland Clinic Foundation | Enzyme encapsulated nanoparticles |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5520912A (en) | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
| WO2001036351A2 (en) | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| WO2001058476A2 (en) * | 2000-02-11 | 2001-08-16 | The European Molecular Biology Laboratory | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity |
| GB0509438D0 (en) | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| CA2662101C (en) * | 2006-08-28 | 2015-07-07 | Omnio Healer Ab | Candidates against infection |
| AU2007290882B2 (en) | 2006-08-28 | 2013-02-21 | Omnio Healer Ab | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| BR112016002753A2 (pt) * | 2013-08-13 | 2017-11-21 | Sanofi Sa | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| TW201722464A (zh) | 2015-11-10 | 2017-07-01 | 波麥堤克生化科學有限公司 | 用於傷口癒合之纖維蛋白溶酶原給藥方案 |
| JP7213552B2 (ja) * | 2016-12-15 | 2023-01-27 | タレンゲン インターナショナル リミテッド | 肝の繊維化を予防及び治療するための方法 |
| CA3047170A1 (en) | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for preventing and treating drug-induced renal injury |
| JP7168990B2 (ja) * | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
-
2018
- 2018-06-15 TW TW107120839A patent/TWI868051B/zh active
- 2018-06-22 KR KR1020207001617A patent/KR20200019217A/ko not_active Ceased
- 2018-06-22 FI FIEP18821458.9T patent/FI3641888T3/fi active
- 2018-06-22 US US16/625,335 patent/US11826404B2/en active Active
- 2018-06-22 DK DK18821458.9T patent/DK3641888T3/da active
- 2018-06-22 BR BR112019027229-1A patent/BR112019027229A2/pt not_active Application Discontinuation
- 2018-06-22 MY MYPI2019007619A patent/MY203136A/en unknown
- 2018-06-22 CA CA3068153A patent/CA3068153A1/en active Pending
- 2018-06-22 SG SG11201912813SA patent/SG11201912813SA/en unknown
- 2018-06-22 AU AU2018287316A patent/AU2018287316B2/en active Active
- 2018-06-22 EP EP18821458.9A patent/EP3641888B1/en active Active
- 2018-06-22 ES ES18821458T patent/ES2965937T3/es active Active
- 2018-06-22 IL IL271470A patent/IL271470B2/en unknown
- 2018-06-22 JP JP2019570806A patent/JP2020524689A/ja active Pending
- 2018-06-22 WO PCT/IB2018/000655 patent/WO2018234861A1/en not_active Ceased
- 2018-06-22 CN CN201880041573.5A patent/CN110831668B/zh active Active
- 2018-06-22 RU RU2020100080A patent/RU2020100080A/ru unknown
- 2018-06-22 MX MX2019015741A patent/MX2019015741A/es unknown
-
2019
- 2019-12-20 CL CL2019003789A patent/CL2019003789A1/es unknown
-
2020
- 2020-01-15 ZA ZA2020/00280A patent/ZA202000280B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL271470A (en) | 2020-01-30 |
| WO2018234861A1 (en) | 2018-12-27 |
| EP3641888A4 (en) | 2021-03-10 |
| AU2018287316A1 (en) | 2020-02-06 |
| DK3641888T3 (da) | 2024-01-02 |
| EP3641888B1 (en) | 2023-10-11 |
| NZ760921A (en) | 2026-01-30 |
| FI3641888T3 (fi) | 2023-12-19 |
| US11826404B2 (en) | 2023-11-28 |
| US20210330761A1 (en) | 2021-10-28 |
| CN110831668A (zh) | 2020-02-21 |
| AU2018287316B2 (en) | 2024-09-19 |
| KR20200019217A (ko) | 2020-02-21 |
| EP3641888A1 (en) | 2020-04-29 |
| ZA202000280B (en) | 2021-08-25 |
| CN110831668B (zh) | 2024-04-12 |
| MY203136A (en) | 2024-06-10 |
| TW201904990A (zh) | 2019-02-01 |
| IL271470B2 (en) | 2025-07-01 |
| SG11201912813SA (en) | 2020-01-30 |
| IL271470B1 (en) | 2025-03-01 |
| RU2020100080A3 (enExample) | 2021-11-02 |
| RU2020100080A (ru) | 2021-07-23 |
| ES2965937T3 (es) | 2024-04-17 |
| MX2019015741A (es) | 2020-11-11 |
| JP2020524689A (ja) | 2020-08-20 |
| CL2019003789A1 (es) | 2020-07-10 |
| TWI868051B (zh) | 2025-01-01 |
| BR112019027229A2 (pt) | 2020-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3641888B1 (en) | Plasminogen treatment of conditions associated with pai-1 overexpression | |
| ES2676422T3 (es) | Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel | |
| Seyfried et al. | A selective cysteine protease inhibitor is non-toxic and cerebroprotective in rats undergoing transient middle cerebral artery ischemia | |
| HK1204932A1 (en) | Pharmaceutical composition for treatment of diabetic complications | |
| WO2015070619A1 (zh) | 鸢尾素在制备预防心肌缺血再灌注损伤的药物中的应用 | |
| Zhu et al. | MMP-9 inhibition alleviates postoperative cognitive dysfunction by improving glymphatic function via regulating AQP4 polarity | |
| US20090318534A1 (en) | Methods and compositions for the treatment of skin diseases and disorders | |
| CA3152346A1 (en) | Methods of treatment for modifying hemodynamics | |
| US20260041663A1 (en) | Prevention of rosacea inflammation | |
| KR20130058669A (ko) | 릴랙신을 사용한 아쿠아포린의 조절 | |
| EP4471154A1 (en) | Use of kinin or derivative thereof in treating vci, psci, or csvd | |
| EP3299382B1 (en) | Oligopeptide having proinflammatory cytokine secretion-inhibiting activity | |
| HK40029531B (en) | Plasminogen treatment of conditions associated with pai-1 overexpression | |
| HK40029531A (en) | Plasminogen treatment of conditions associated with pai-1 overexpression | |
| CN110511266B (zh) | 一种小分子多肽及其用途 | |
| US11439713B2 (en) | Method for creating a renal injury model to screen molecules for the treatment of renal injury | |
| US7375076B2 (en) | Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein | |
| Clough et al. | Microdialysis—a model for studying chronic wounds | |
| EP3909599A1 (en) | Method for preventing, treating or delaying myocardial damage using neuregulin and composition | |
| JP2002522396A (ja) | 乾癬治療用プロテアーゼ阻害因子 | |
| JP6289511B2 (ja) | 羊水塞栓の治療剤 | |
| WO2019048898A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230613 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241016 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250117 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250227 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250329 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250521 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250521 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250522 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250522 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250526 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250526 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260302 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260312 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260521 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260521 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-4-4-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20260702 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260710 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260710 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260728 |